61 results
Page 2 of 4
6-K
EX-99.1
ad0oa
9 Dec 21
Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer
7:30am
6-K
EX-99.1
oxrr tcflw
22 Oct 21
Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy
6:02am
424B5
zv7ze8yh
9 Jun 21
Prospectus supplement for primary offering
4:54pm
6-K
EX-99.1
s1utirlp9ry qmwodjm
4 Jun 21
Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
8:01am
20-F/A
zl34dczici7rmx
16 Mar 21
Annual report (foreign) (amended)
3:22pm
6-K
EX-99.1
a9g ahqw4c82
3 Mar 21
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
8:23am
POS AM
hk8 r9axszyo16q
10 Jul 20
Prospectus update (post-effective amendment)
4:35pm
F-3
bbm76f y3tai
10 Jul 20
Shelf registration (foreign)
4:31pm
6-K
EX-99.1
59j8h5u8f2pxr
2 Jul 20
Extraordinary General Meeting of Shareholders
4:19pm
6-K
EX-99.1
yalq 6klnf
2 Jul 20
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update
8:35am
424B5
ol9juxb4oqnh nav3
25 Jun 20
Prospectus supplement for primary offering
11:13am
F-3
0w082s
13 May 20
Shelf registration (foreign)
4:32pm
424B5
h35c4mqphuqqvkgr0ff
8 May 20
Prospectus supplement for primary offering
10:40am
424B4
e23ol2
16 Mar 20
Prospectus supplement with pricing info
6:08am
F-1/A
mvgd2krhc54gtw5y5
11 Mar 20
Registration statement (foreign) (amended)
9:16am
F-1/A
oupe231ozcgzq
10 Mar 20
Registration statement (foreign) (amended)
8:13am
6-K
EX-99.1
751xrtmy 87c0jtzi
9 Jan 20
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
9:03am
424B3
y8au lzij0lvy68g5v5
27 Dec 19
Prospectus supplement
4:30pm